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Abstract
Background: Limited studies examine the immune landscape in Esophageal Adenocarcinoma (EAC). We aim to
identify novel associations, which may inform immunotherapy treatment stratification.
Methods: Three hundred twenty-nine EAC cases were available in Tissue Microarrays (TMA) format. A discovery
cohort of 166 EAC cases were stained immunohistochemically for range of adaptive immune (CD3, CD4, CD8 and
CD45RO) and immune checkpoint biomarkers (ICOS, IDO-1, PD-L1, PD-1). A validation cohort of 163 EAC cases was
also accessed. A digital pathology analysis approach was used to quantify biomarker density.
Results: CD3, CD4, CD8, CD45RO, ICOS and PD-1 were individually predictive of better overall survival (OS) (Log
rank p = < 0.001; p = 0.014; p = 0.001; p = < 0.001; p = 0.008 and p = 0.026 respectively). Correlation and multivariate
analysis identified high CD45RO/ICOS patients with significantly improved OS which was independently prognostic
(HR = 0.445, (0.223–0.886), p = 0.021). Assessment of CD45RO and ICOS high cases in the validation cohort revealed
an associated with improved OS (HR = 0.601 (0.363–0.996), p = 0.048). Multiplex IHC identified cellular co-expression
of high CD45RO/ICOS. High CD45RO/ICOS patients have significantly improved OS.
Conclusions: Multiplexing identifies true cellular co-expression. These data demonstrate that co-expression of
immune biomarkers are associated with better outcome in EAC and may provide evidence for immunotherapy
treatment stratification.
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Background
Esophageal cancer (EAC) incidence has increased several
fold in the last 30 years and is responsible for over four
hundred thousand deaths globally per annum (http://
www.cancerresearchuk.org/health-professional/
oesophageal-cancer-statistics), with adenocarcinoma
now the dominant histology reported in the Western
world [1]. As well as surgery, the current treatment regi-
mens include cytotoxic chemotherapy and radiation and
are associated with significant morbidity. Five year sur-
vival rates remain poor at 17% and for resectable disease
this figure remains at approximately 45% despite im-
provements in surgery and neo-adjuvant therapy. The
wide variability in patient outcome following resection is
indicative of the need for robust biomarkers for prog-
nostication, even following the improved survival rates
seen with the introduction of neo-adjuvant chemother-
apy [2, 3]. There is an urgent need for targeted therapies
and deeper understanding of EAC.
Response to checkpoint inhibition has been shown to
be more effective in tumours with a higher mutational
load [4]. These tumour types are increasingly being con-
sidered as potential targets for immunotherapy. EAC is
one example of a tumour type with a high mutational
frequency with as many as three hundred thousand mu-
tations per tumour [5].
The immune context of the tumour microenvironment
(TME) comprise a range of regulatory proteins which,
upon activation, can inhibit effective T-cell response
leading to antitumor immunity. This regulation is a vital
checkpoint in the inflammatory cascade, which many
tumour types are able to evade. However, there have
been recent success with checkpoint inhibition in solid
tumours where increased expression of checkpoint pro-
teins has been associated with a poor clinical outcome
[6, 7]. This has been specifically demonstrated for EAC
[8–10]. There is evidence that PD-L1 expression in EAC
tumours is predictive of response in phase 1 trials,
NCT01928394, NCT01943461 and NCT01772004 re-
ported in a recent meta-analysis [11]. Nevertheless, in-
creasing data suggest that expression of PD-L1 alone
may not be adequate to be predict response due to the
lack of response seen in many PD-L1 expressing tu-
mours [12, 13]. This is further compounded by re-
sponses reported in PD-L1 negative cases [14].
Consequently, there has been a shift in focus to the im-
mune contexture of the TME to identify cell phenotypes
which may serve as prognostic biomarkers [15, 16].
These efforts including identification, quantification and
spatial analysis of tumour-infiltrating lymphocytes and
other immune and immune checkpoint biomarkers.
We report here on the immunohistochemical expres-
sion of several T cell linage markers and immune check-
point biomarkers and their combinatorial influence on
EAC outcome. We highlight a potential therapeutic ad-
vantage for a subset of patients and discuss the survival
impact of immunological factors.
Methods
Ethical approval, patient material and tissue microarray
creation
Following ethical approval, a discovery cohort of 166
EAC cases were made available across seven TMAs.
Prior to surgical resection, patients received neo-
adjuvant chemotherapy. Median follow up time was
48.8 months. Clinicopathological details are shown in
Table 1 and have recently been described for the cohort
[17, 18]. Of these 166 cases, 145 cases had sufficient
tumour volume and biomarker data available for analysis
with matched clinical information. Cases were diagnosed
in Northern Ireland from 2004 to 2012 with ethical ap-
proval granted by the Northern Ireland Biobank (NIB15/
0168) and ORECNI (13-NI-0149) [19]. A validation set
of 163 resected gastro-oesophageal adenocarcinoma
cases represented on five TMA was obtained from the
Grampian biorepository, diagnosed within the Grampian
National Health Service Scotland from 2004 to 2010,
accessed through the Grampian Biorepository (OREC
18/LO/0161), which has been previously described [20].
The construction of the TMAs was three 1-mm diam-
eter cores were taken from the central tumour region
from each representative resection tumour FFPE block in
the discovery cohort and two 1-mm diameter cores were
taken from the central tumour region for the validation
cohort. Cores were only taken from cases containing
tumour. Tumours with regression and regions containing
scarring or inflammation only were not sampled. TMAs
were created using a Beecher Manual Arrayer®.
Immunohistochemistry
Immunohistochemical analysis was performed within the
Precision Medicine Centre of Excellence. Slides were im-
munostained on a Ventana BenchMark or Leica Bond Rx
fully automated immunostainers, with previously validated
antibodies for CD3, CD4, CD8, CD45RO, ICOS, IDO-1,
PD-L1 and PD-1 (Table S1). Briefly, antigen retrieval using
cell conditioning solution 1 (CD3, CD4, PD-L1 and PD-1)
or epitope retrieval solution 2 (CD8, CD45RO, ICOS,
IDO-1) was performed. Optimised antibody concentra-
tions were incubated according to the manufacturer in-
structions. Bound antibody was detected with Ultraview
DAB/Optiview DAB Kits (Roche) or Bond Polymer Refine
Detection Kit (Leica). Following initial microscopic quality
control, all slides were digitised on a Leica Aperio AT2
scanner at × 40 magnification.
Multiplexing of CD45RO/ICOS/Cytokeratin (CK)/
DAPI was conducted on a Leica Bond Rx fully auto-
mated immunostainer, with validated antibodies for
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CD45RO, ICOS and CK using the Opal Multiplex Im-
munostaining kit (PerkinElmer; Waltham, MA) accord-
ing to the manufacturer’s instructions (Supplementary
Table S1). Briefly, antigen retrieval was performed using
epitope retrieval solution 2, validated CK was applied
followed by the Opal 520 fluorophore at the working
concentration. Unbound antibody was removed with
heat-meditated retrieval. The process was repeated for
two additional rounds for CD45RO and ICOS followed
by secondary labelling with the respective fluorophores
(Opal 570 and Opal 690, respectively). Nuclei were la-
belled with DAPI for 10 min. Immunofluorescent slides
were digitised on a Vectra Polaris fluorescent scanner at
× 40 magnification.
Optimised DAB biomarker expression was evaluated
by and agreed upon with a senior consultant pathologist
prior to the study. Assessment of each DAB biomarker
was undertaken using open-source software QuPath
[21]. Assessment of fluorescent Multiplex slides was
conducted using the Vectra Polaris inForm software ac-
cording to established workflows. Digital image analysis
was carried out, blinded to clinical data, according to cell
detection algorithms defined for each biomarker under
the direction of senior consultant pathologists and/or a
senior principal clinical scientist (MST, JJ and SMcQ) to
determine the number of positive cells per mm2. Briefly,
TMAs were de-arrayed, tissue detection was performed
by identifying the tissue for cellular analysis. Samples
containing less than 100 tumour cells were excluded
from analysis. Rigorous quality control (QC) steps were
taken to remove necrosis or keratin, tissue folds, en-
trapped normal structures and confirm data consistency
across TMAs cores from the same tumour; this was con-
firmed by a second reviewer with frequent consultation,
with case consensus decisions taken if TMA core data
was highly discordant, following an established method,
previously described [21–25].
This study was performed and reported in line with
the REMARK criteria [26].
Statistical analysis
Biomarkers were dichotomised using a cut off (Supple-
mentary Table S2) derived by receiver operator curve
(ROC) employing Euclidean distance methodology to
determine optimum sensitivity and specificity value. As-
sociations with Overall Survival (OS) (OS; from initial
diagnosis to death) were analysed by Kaplan–Meier sur-
vival analysis, reporting log rank p values. Patients were
censored at the last day they were known to be alive.
Variables were entered in univariate and multivariate
analysis included Mandard tumour regression grading, T
stage, N Stage, nodal status and circumferential resec-
tion margin involvement defined as tumour cells at or
within 1 mm of the margin, as is routinely used in
Table 1 Clinicopathological data for discovery and validation
cohorts
Characteristics Discovery TMA
N = 145 (%)
Validation TMA
N = 163 (%)
Age
< 60 42 (29%) 47 (29%)
= > 60 103 (71%) 115 (71%)
Unknown 0 (0%) 1 (< 1%)
Sex
Male 115 (79%) 117 (72%)
Female 30 (21%) 46 (28%)
Tumour site
Esophagus 8 (6%) 71 (44%)
Stomach 0 (0%) 92 (56%)
GOJ, Siewert 1 81 (56%) 0 (0%)
GOJ, Siewert 2 44 (30%) 0 (0%)
GOJ, Siewert 3 12 (8%) 0 (0%)
T Stage
pT0/1 3 (2%) 24 (15%)
pT2 11 (8%) 55 (34%)
pT3 117 (81%) 81 (49%)
pT4 2 (1%) 3 (2%)
Unknown 12 (8%) 0 (0%)
N Stage
N0 33 (23%) 72 (44%)
N1 85 (59%) 74 (45%)
N2/3 3 (2%) 17 (11%)
Unknown 24 (16%) 0 (0%)
Lymph node
Positive 97 (67%) 91 (56%)
Negative 48 (33%) 72 (44%)
Mandard TRG
1 1 (< 1%) 0 (0%)
2 8 (6%) 6 (4%)
3 28 (19%) 14 (9%)
4 69 (48%) 25 (15%)
5 33 (23%) 20 (12%)
Unknown 6 (4%) 67 (41%)
No Chemotherapy 0 (0%) 31 (19%)
Margin Involvement
Positive 63 (43%) 39 (24%)
Negative 79 (55%) 124 (76%)
Unknown 3 (2%) 0 (0%)
Neo-adjuvant chemotherapy
Yes 145 (100%) 85 (52%)
No 0 (0%) 66 (41%)
Missing 0 (0%) 12 (7%)
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analysis of EAC datasets. Hazard ratios (HR) and P
values reported for univariate and multivariate analysis
were calculated using Cox proportional hazards regres-




Cellular expression of CD3, CD4, CD8 and CD45RO
was observed as strong membrane staining as expected,
with characteristic, strong and fine, membrane staining
seen for the PD-L1 clone SP263. ICOS, IDO-1, PD-1
displayed both nuclear and cytoplasmic staining with a
weak cytoplasmic blush. Examples of optimised and vali-
dated staining on TMA cores are shown in Fig. 1.
Immune checkpoint biomarkers impact overall survival
Whole core scores were assessed for each single IHC
biomarker and were generated using a robust digital
pathology workflow, figure S1. Biomarkers in the discov-
ery cohort were quantified by the density of positive cells
per mm2 for CD3, CD4, CD8 and CD45RO. Kaplan
Meier survival analysis showed that high CD3, CD4,
CD8 and CD45RO were significantly associated with
better OS (Fig. 2a, b, c and d, Log rank p = < 0.001;
0.001; 0.001 and < 0.001, respectively).
Following assessment of adaptive immune biomarkers, a
series of immune checkpoint biomarkers (ICOS, IDO-1,
PD-1 and PD-L1) were also assessed in the discovery co-
hort by density of positive cells per mm2, with the excep-
tion of IDO-1 and PD-L1. PD-L1 scoring was assessed by
percentage tumour positivity using established clinically
relevant thresholds for non-small cell lung cancer
(NSCLC) (< 1%, 1–49% or > 50% tumour epithelial cell
positivity). Due to the low number of cases positive for
IDO-1 manual assessment in the tumour only, stroma
only and whole core was the most optimal method using a
(0 = 0%, 1 = 1–33%, 2 = 34–66%, 3 ≥ 66%) scoring system
reported for IDO-1 assessment in breast cancer tissue
[27]. Kaplan Meier survival analysis showed that high ex-
pression of ICOS and PD-1 but not IDO-1 and PD-L1
were associated with significantly better OS (Fig. 2e, f, g
and h, Log rank p = 0.008; 0.026; 0.918 and 0.182, respect-
ively). IDO-1 expression was observed in several cases to
be exclusively expressed within intra-tumoural nests or
exclusively to the stroma, as well as combinations of both.
Therefore, tissue compartment expression assessment was
undertaken for IDO-1. There was no impact on OS for
IDO-1 irrespective of cellular location (Fig. 2g). Adaptive
immune and immune checkpoint associations by univari-
ate analysis are shown in Table 2.
To observe correlations between multiple biomarkers
a correlation matrix was created displaying associations
by spearman rank (Fig. 3). Positive correlations were
represented in blue text with a circle corresponding to
the magnitude of the correlation by size. Unsurprisingly,
the highest correlation was CD3:CD8 (r2 = 0.83) while
the lowest correlation was seen with CD3:IDO-1 (r2 =
0.16).
The impact of each immunological biomarker on OS
was assessed in a multivariate model, which contained
potential confounding clinicopathological factors. When
evaluated in multivariate analysis CD45RO and ICOS
co-expression remained independently prognostic (Table
2).
Co-expression of immune biomarkers reveals immune hot
and cold patient populations
Identification of a patient population, we described here
as ‘immune hot’ (high CD3, CD4, CD8, CD45RO, ICOS,
PD-1 and PD-L1), was observed. In contrast to a counter
population of negatively expressing ‘immune cold’ cases,
there was a striking variance in survival advantage for
the ‘immune hot’ population (Fig. 4a). The ‘immune hot’
group had significantly better outcome over five-years
compared to the ‘immune cold’ group, 74 and 11%, re-
spectively (Log rank p = 0.022). However, due to the low
number of cases for within these groups (n = 23), we
must resist over-interpretation. As stated, CD45RO and
ICOS remained independently prognostic in multivariate
analysis. Therefore, examination of patient populations
within this enriched phenotype of high CD45RO/ICOS
was assessed against its contrasting population of low
CD45RO/ICOS (Fig. 4b) (N = 65). Co-expression of high
CD45RO and ICOS conferred a significant survival ad-
vantage over five-years, 65% (high/high) and 8% (low/
low), respectively (Log rank p = < 0.001).
High CD45RO/ICOS co-expression is positively prognostic
in EAC
Having identified the positive prognostication of CD45RO
and ICOS co-expression in the discovery cohort, Table 2,
which remained significant upon multivariate analysis
(cox regression p = 0.021; HR, 0.445 (0.223–0.886), Table
2), and that demonstrated a high correlation, we examined
the IHC expression in a validation cohort of a further 163
EAC [20]. The observed relationship in the discovery co-
hort was also seen in the validation cohort (log rank p =
0.045, Fig. 5; cox regression p = 0.048; HR, 0.601 (0.363–
0.996), Table 2). This association however did not remain
upon multivariate analysis in the validation set when ad-
justed for confounding factors (cox regression p = 0.639;
HR, 0.810 (0.336–1.953), Table 2).
Multiplexing reveals true cellular co-expression of
immune biomarkers
In order to identify whether a population of truly high
CD45RO/ICOS co-expressing cells is present in these
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Fig. 1 Optimised biomarkers staining for the immune and immune checkpoint proteins quantified. Each TMA core (10x) shows a case where DAB
staining was clear and quantifiable. Each panel contains a magnified view of the staining at 40x
Fig. 2 Adaptive immune and Immune checkpoint biomarker expression impact on five-year patient survival. Dichotomisation was based on the
cut-off calculated using a ROC curve. Cases falling into the high group are represented by the red line with the blue line representing low
expression for a CD3, b CD4, c CD8, d CD45RO, e ICOS and f PD-1. g IDO-1, was dichotomised based on expression of the biomarker in tumour,
stroma or both, while h PD-L1, was grouped based on clinically established cut-off points (< 1%, 1–49 and > 50%). For IDO-1 and PD-L1 the
dichotomisation is represented in the key for each biomarkers respectively. Log-rank p values are shown for each graph
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patients, as opposed to a simultaneous increase in indi-
vidually positive cells, a CD45RO/ICOS/CK/DAPI multi-
plex was conducted. Cases were identified from the prior
determined ‘immune hot’ and ‘immune cold’ patient pop-
ulations. Blinded to clinical data, whole core analysis was
conducted digitally. Cellular co-expression was considered
true when an individual cell was positive for both
CD45RO and ICOS biomarkers (Fig. 6a). Tissue compart-
mental analysis demonstrated a statistically significant dif-
ference observed between the ‘immune hot’ group
compared with the ‘immune cold’ for both stromal ICOS
and stromal CD45RO, Fig. 6b and c respectively, parallel-
ing the whole assessment in the chromogenic DAB IHC
data, Fig. 2. We observed a significant difference in the
cellular co-expression of positive CD45RO/ICOS cells
within stroma in the ‘immune hot’ group compared with
the ‘immune cold’ group (p = 0.049), Fig. 6d. There was
no co-expression of CD45RO/ICOS positive cells within
tumour nests, Fig. 6d.
Discussion
Here, we described the immunophenotypic landscape of
EAC and describe the existence of an ‘immune hot’
Table 2 Univariate and Multivariate analysis of clinicopathological factors and immune and immune checkpoint biomarkers in EAC
in the discovery and validation cohorts
Variables Discovery Validation
HR (95% CI) p-value HR (95% CI) p-value
Univariate Analysis
Mandard 1.36 (1.032–1.792) 0.029 1.833 (1.223–2.898) 0.004
T Stage 0.879 (0.7058–1.095) 0.25 1.764 (1.286–2.418) < 0.001
N Stage 1.125 (0.7588–1.667) 0.558 1.473 (1.156–1.878) 0.002
Node Pos 1.03 (1.022–1.039) < 0.001 2.180 (1.374–3.460) 0.001
CRM Involved 3.533 (2.238–5.576) < 0.001 1.258 (1.093–1.447) 0.001
CD3 0.4521 (0.2929–0.6977) < 0.001 – –
CD4 0.6087 (0.3897–0.9509) 0.029 – –
CD8 0.4932 (0.3188–0.7629) 0.001 – –
CD45RO 0.4271 (0.2587–0.7052) < 0.001 0.835 (0.546–1.278) 0.407
ICOS 0.5346 (0.3447–0.8291) 0.005 0.656 (0.424–1.015) 0.059
PD-1 0.540 (0.337–0.866) 0.010 – –
IDO-1 0.95 (0.7935–1.137) 0.577 – –
PD-L1 0.762 (0.570–10.19) 0.067 – –
CD45RO/ICOS 0.394 (0.210–0.740) 0.003 0.601 (0.363–0.996) 0.048
Multivariate Analysis
Mandard 1.321 (0.938–1.862) 0.111 2.078 (1.161–3.718) 0.014
T Stage 0.6846 (0.4968–0.943) 0.020 0.926 (0.397–2.160) 0.859
N Stage 1.264 (0.722–2.211) 0.412 1.759 (0.709–4.365) 0.223
Node Pos 1.0183 (1.006–1.0300) 0.002 0.482 (0.117–1.984) 0.312
CRM Involved 2.214 (1.2663–3.8711) 0.002 1.171 (0.842–1.628) 0.349
CD45RO/ICOS 0.445 (0.223–0.886) 0.021 0.810 (0.336–1.953) 0.639
Fig. 3 Correlation matrix displaying spearman rank. Positive
correlation is represented in blue. The size of the circle corresponds
to the magnitude of the correlation
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subgroup of patients that confers a significant survival
advantage. Further delineation of only high CD45RO/
ICOS cases was then investigated, informed by multi-
variate and correlative analysis, improving patient inclu-
sion, stratification and OS advantage. We also describe,
by multiplex immunofluorescence, co-expression of
CD45RO/ICOS positive cells in these cases, observing a
significant difference across the contrasting immune
groups. Interrogation of dual labelled cell expression
within the tumour and stroma revealed that stromal co-
expression was significantly increased in the ‘immune
hot’ group.
Efforts towards a better understanding the tumour-
immune milieu of EAC are gradually increasing. We be-
lieve our collaborative study, inclusive of a validation
EAC cohort, is the largest of its kind reported to date.
Making these data one of very few comprehensive publi-
cations delineating immune biomarkers in EAC.
Fig. 4 Five-year patient survival of ‘immune hot’ and high CD45RO/ICOS co-expressed cases in the discovery cohort. a Patients designated
‘immune hot’, expressing high level of CD45RO, ICOS, CD3, CD4, CD8, PD-1 and PD-L1 are in blue, contrasted with red where patented do not
express these markers. b Patients expressing high CD45RO/ICOS, blue vs. low CD45RO/ICOS, red. Table below each graph displays number of
patients in each group at specified time points, in brackets is the number of censored patients
Fig. 5 Five-year survival of patients expressing high CD45RO/ICOS vs low CD45RO/ICOS in the validation cohort. Cases falling into the high group
are represented by the red line with the blue line representing low expression
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In some tumour types, NSCLC for example, there is
extensive data supporting the assessment of PD-L1 pro-
tein expression as a good predictor of patient response
to immunotherapy. The evidence is scant for such appli-
cation in EAC, owing mainly to the wide-ranging expres-
sion patterns seen in EAC. Recent results of Keynote 62
study reported that pembrolizumab to first line chemo-
therapy did not show any benefit [13]. Though mem-
branous epithelial expression has been reported in EAC,
which was also observed in our study, PD-L1 expression
has been predominantly observed in the surrounding
tumour-stroma rather than the membranes of epithelial
cells, as reported in KEYNOTE-012 and observationally
by others [28–30]. This is in addition to the subjective
and challenging pathological assessment of PD-L1,
which may complicate the adoption of the diagnostic
test [24]. Recently, negative prognostication of PD-L2
was reported for esophageal cancer. Though this is was
mainly in squamous cell carcinoma, the authors found
no significant correlation between PD-L2 and PD-L1 ex-
pression. However, these data may indicate evaluation of
both PD-L2 and PD-L1 expression may be clinically im-
portant [31].
Attempts to assess densities of T cells in EAC have
been made. The expression of high CD3, CD4, CD8 and
FOXp3 cells in EAC was reported in 128 cases, where all
markers achieved significance in univariate analysis,
closely mirroring our own data. However, only high
CD8 cells alone reached positive prognostic significance
in multivariate analysis [32]. A similarly powered study
demonstrated significance on OS by all markers (CD3,
CD8 and FoxP3). Though CD8 positive T cell expression
has been shown to be positively prognostic in EAC [33],
Thompson et al, recently demonstrated that high CD8
infiltration was correlated with impaired progression free
survival and OS [28]. These data directly contrast with
our own, where we demonstrate, as with several afore-
mentioned studies that increased CD8 densities corre-
lated with improved OS. We believe disparities are likely
due our increased cohort numbers, robust digital path-
ology quantification methodology and a statistically de-
rived cut-offs in comparison to a lower sample numbers
and alternatively defined dichotomisations (median and
quartile thresholds).
We acknowledge weaknesses in our study such as the
limited number of cases interrogated by multiplex,
restricting our assessment of the impact on survival by
these CD45RO/ICOS positive dual labelled cells. Never-
theless, in these few exemplar cases we demonstrate a
statistically significant difference in expression of these
Fig. 6 Multiplex co-expressing case displaying dual CD45RO/ICOS positive cell expression. a displays a TMA core multiplex image with an
exploded view of a tumour and stromal region via individual fluorescence channels with dual labelled CD45RO/ICOS positive cells identified in
the composite. b and c show graphically the assessment data for both ICOS and CD45RO, respectively, in both the tumour (blue) and stroma
(red) for both ‘immune hot’ (n = 4) and ‘immune cold’ (n = 3) groups. d presents the cellular co-expression of CD45RO/ICOS positive cells within
tumour (blue) and stroma (red) for both ‘immune hot’ (n = 4) and ‘immune cold’ (n = 3) groups. P values are two tailed t-tests assessing stromal
biomarker expression across the two groups
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dual labelled cells across ‘immune hot’ and ‘immune
cold’ patient groups, which have individually and to-
gether shown survival impact by single chromogenic
DAB IHC. The limited number of TRG 1 and 2 cases in
our cohort has the potential to confound our analysis.
To examine this, we undertook an analysis inclusive of
only TRG3 and higher. No difference was observed and
CD45RO/ICOS positive cases remained significantly
positive prognostic by multivariate analysis (Supplemen-
tary Table S3). We acknowledge the increased number
of gastric case in the validation cohort, which are poten-
tially more inflammatory due to being potentially MSI
high or EBV positive. MSI/EBV status is unexplored in
this cohort. We also accept the retrospective, post-
treatment nature of the cohort and recognise that pre-
operative treatment may likely to induce a permanent or
transient change in the immune microenvironment of
EAC [34]. We ideally would wish to compare and con-
trast the immune profiles of a surgery only cohort, with-
out chemo/chemoradiation treatment, in comparison
with our data here. With few patients going straight to
surgery without some form of treatment, we are unable
to obtain samples from a suitable historical cohort of
sufficient size to explore this question. However, this co-
hort is representative of current clinical practice.
It is rational to assume that PD-L1 inhibitors may have
applicability in EAC. However, studies have demon-
strated contrasting prognostication of PD-L1 expression
in EAC [8–10, 35]. Interestingly, as with PD-L1, we ob-
serve that ICOS, a member of the B7-family of proteins,
as is PD-L1, was expressed predominantly in the stroma,
conferring a positive prognostic survival advantage. Our
data add support to the hypothesis that some of the
more novel B7-family members could be regulating CD4
T-cell differentiation toward specific effector cell pheno-
types. Indeed, ICOS/CD4 correlation has been reported
in colorectal cancer, where expression is associated with
improved survival and may be a clinical biomarker for
good prognosis [36]. Here, we show the association of
CD45RO/ICOS as being greater than that of ICOS/CD4
which maybe highlighting a previously unreported popu-
lation of ICOS positive memory cells, which encompass
CD4. The prognostication of high ICOS/CD4 cells may
be being enhanced in our study, by evaluation of all
CD45RO positive cells, which include; all memory T
cells, B cell subsets, activated monocytes/macrophages
and granulocytes, not solely a subpopulation of CD4
positive cells. Our data emphasise the scrutiny required
when analysing experimental and trail data to consider
1) The specific cell phenotype of interest. 2) The expres-
sion of the target. 3) The expression of associated pro-
teins and ligands. 4) The specificity of the antibody used.
Our data may yet be corroborated in clinical trial data
with the ICOS agonist GSK3359609 (GlaxoSmithKline,
London, UK), currently evaluated in a phase I trial
INDUCE-1, NCT02723955. As well as JTX-2011, (Jounce
Therapeutics, Cambridge, USA) in phase I/II ICONIC
trial, NCT02904226. Future work aims to assess
CD45RO/ICOS positive dual labelled cells by multiplexing
in a large cohort of cases to assess impact on survival.
Conclusion
We describe the existence of both ‘immune hot’ and ‘im-
mune cold’ patient populations in EAC. Several immune
biomarkers examined were shown to be positively prog-
nostic for OS. Upon correlative and multivariate ana-
lysis, we identified a high CD45RO/ICOS subgroup of
patients, with co-expression of these biomarkers, strati-
fying patients in to contrasting survival groups. Multi-
plexing revealed dual labelled CD45RO/ICOS positive
cells to be expressed in the stromal compartment of
EAC tissue. These dual labelled cells were significantly
differentially expressed across the ‘immune hot’ and ‘im-
mune cold’ patient populations. In summary, we have
identified a subpopulation of high CD45RO/ICOS EAC
patients with significant positive prognostication. More-
over, these data provide evidence for the assessment of
CD45RO/ICOS to be employed in the stratification of
patients for clinical trials investigating the response to
immunotherapy.
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